Roche has secured FDA approval for its new breast cancer drug, Wilserdly, for advanced or metastatic cases. This approval marks a significant milestone for Roche, as the drug is projected to be a future top-seller with over $3.57 billion in peak annual sales, potentially boosting the company's revenue and market position.
Roche received FDA approval for Wilserdly (giredestrant), its new oral breast cancer treatment, for advanced or metastatic cases in combination with Novartis's Afinitor. This is a significant positive development for Roche, as Wilserdly is projected to be a blockbuster drug, potentially generating over $3.57 billion in peak annual sales. This approval provides a short-term boost to Roche's pipeline and long-term revenue growth prospects. For traders, this represents an opportunity to capitalize on Roche's strengthened market position and future earnings potential, especially as the company seeks approval for earlier disease phases, which would further expand its market.